References:
[1] Bonvalot S, Rivoire M, Castaing M, Stoeckle E, Le Cesne A, Blay
JY, Laplanche A. Primary retroperitoneal sarcomas: a multivariate
analysis of surgical factors associated with local control. J Clin
Oncol. 2009 Jan 1;27(1):31-7. doi: 10.1200/JCO.2008.18.0802. Epub 2008
Dec 1. PMID: 19047280.
[2] Raut CP, Pisters PW. Retroperitoneal sarcomas: Combined-modality
treatment approaches. J Surg Oncol. 2006 Jul 1;94(1):81-7. doi:
10.1002/jso.20543. PMID: 16788949.
[3]Porter GA, Baxter NN, Pisters PW. Retroperitoneal sarcoma: a
population-based analysis of epidemiology, surgery, and radiotherapy.
Cancer. 2006 Apr 1;106(7):1610-6. doi: 10.1002/cncr.21761. PMID:
16518798.
[4] Mann GN, Mann LV, Levine EA, Shen P. Primary leiomyosarcoma of
the inferior vena cava: a 2-institution analysis of outcomes. Surgery.
2012 Feb;151(2):261-7. doi: 10.1016/j.surg.2010.10.011. Epub 2010 Dec
22. PMID: 21176932.
[5] Ito H, Hornick JL, Bertagnolli MM, George S, Morgan JA, Baldini
EH, Wagner AJ, Demetri GD, Raut CP. Leiomyosarcoma of the inferior vena
cava: survival after aggressive management. Ann Surg Oncol. 2007
Dec;14(12):3534-41. doi: 10.1245/s10434-007-9552-z. Epub 2007 Sep 25.
PMID: 17896156.
[6]Kieffer E, Alaoui M, Piette JC, Cacoub P, Chiche L.
Leiomyosarcoma of the inferior vena cava: experience in 22 cases. Ann
Surg. 2006 Aug;244(2):289-95. doi: 10.1097/01.sla.0000229964.71743.db.
PMID: 16858193; PMCID: PMC1602179.
[7] Illuminati G, Calio’ FG, D’Urso A, Giacobbi D, Papaspyropoulos
V, Ceccanei G. Prosthetic replacement of the infrahepatic inferior vena
cava for leiomyosarcoma. Arch Surg. 2006 Sep;141(9):919-24; discussion
924. doi: 10.1001/archsurg.141.9.919. PMID: 16983035.
[8]. Hollenbeck ST, Grobmyer SR, Kent KC, Brennan MF. Surgical
treatment and outcomes of patients with primary inferior vena cava
leiomyosarcoma. J Am Coll Surg. 2003 Oct;197(4):575-9. doi:
10.1016/S1072-7515(03)00433-2. PMID: 14522326..
[9] Stoeckle E, Coindre JM, Bonvalot S, Kantor G, Terrier P,
Bonichon F, Nguyen Bui B; French Federation of Cancer Centers Sarcoma
Group. Prognostic factors in retroperitoneal sarcoma: a multivariate
analysis of a series of 165 patients of the French Cancer Center
Federation Sarcoma Group. Cancer. 2001 Jul 15;92(2):359-68. doi:
10.1002/1097-0142(20010715)92:2<359::aid-cncr1331>3.0.co;2-y.
PMID: 11466691.
[10] Weiss SW, Rao VK. Well-differentiated liposarcoma (atypical
lipoma) of deep soft tissue of the extremities, retroperitoneum, and
miscellaneous sites. A follow-up study of 92 cases with analysis of the
incidence of ”dedifferentiation”. Am J Surg Pathol. 1992
Nov;16(11):1051-8. doi: 10.1097/00000478-199211000-00003. PMID: 1471725.
[11] Storm FK, Mahvi DM. Diagnosis and management of retroperitoneal
soft-tissue sarcoma. Ann Surg. 1991 Jul;214(1):2-10. doi:
10.1097/00000658-199107000-00002. PMID: 2064467; PMCID: PMC1358407.
[12] Messiou C, Moskovic E, Vanel D, Morosi C, Benchimol R, Strauss
D, Miah A, Douis H, van Houdt W, Bonvalot S. Primary retroperitoneal
soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic
algorithm. Eur J Surg Oncol. 2017 Jul;43(7):1191-1198. doi:
10.1016/j.ejso.2016.10.032. Epub 2016 Dec 9. PMID: 28057392.
[13] Liles JS, Tzeng CW, Short JJ, Kulesza P, Heslin MJ.
Retroperitoneal and intra-abdominal sarcoma. Curr Probl Surg. 2009
Jun;46(6):445-503. doi: 10.1067/j.cpsurg.2009.01.004. PMID: 19414097.
[14] Jaques DP, Coit DG, Hajdu SI, Brennan MF. Management of primary
and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg. 1990
Jul;212(1):51-9. doi: 10.1097/00000658-199007000-00008. PMID: 2363604;
PMCID: PMC1358074
[15] Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal
soft-tissue sarcoma: analysis of 500 patients treated and followed at a
single institution. Ann Surg. 1998 Sep;228(3):355-65. doi:
10.1097/00000658-199809000-00008. PMID: 9742918; PMCID: PMC1191491.
[16] Hassan I, Park SZ, Donohue JH, Nagorney DM, Kay PA, Nasciemento
AG, Schleck CD, Ilstrup DM. Operative management of primary
retroperitoneal sarcomas: a reappraisal of an institutional experience.
Ann Surg. 2004 Feb;239(2):244-50. doi:
10.1097/01.sla.0000108670.31446.54. PMID: 14745333; PMCID: PMC1356218.
[17] Catton CN, O’Sullivan B, Kotwall C, Cummings B, Hao Y,
Fornasier V. Outcome and prognosis in retroperitoneal soft tissue
sarcoma. Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10. doi:
10.1016/0360-3016(94)90395-6. PMID: 8083069.
[18] Lehnert T, Cardona S, Hinz U, Willeke F, Mechtersheimer G,
Treiber M, Herfarth C, Buechler MW, Schwarzbach MH. Primary and locally
recurrent retroperitoneal soft-tissue sarcoma: local control and
survival. Eur J Surg Oncol. 2009 Sep;35(9):986-93. doi:
10.1016/j.ejso.2008.11.003. Epub 2009 Jan 12. PMID: 19138832.
[19] Anaya DA, Lev DC, Pollock RE. The role of surgical margin
status in retroperitoneal sarcoma. J Surg Oncol. 2008 Dec
15;98(8):607-10. doi: 10.1002/jso.21031. PMID: 19072853.
[20] Pierie JP, Betensky RA, Choudry U, Willett CG, Souba WW, Ott
MJ. Outcomes in a series of 103 retroperitoneal sarcomas. Eur J Surg
Oncol. 2006 Dec;32(10):1235-41. doi: 10.1016/j.ejso.2006.07.002. Epub
2006 Aug 21. PMID: 16919908.
[21] Avancès C, Mottet N, Mahatmat A, Chapuis E, Serre I, Culine S.
Prognostic factors for first recurrence in patients with retroperitoneal
sarcoma. Urol Oncol. 2006 Mar-Apr;24(2):94-6. doi:
10.1016/j.urolonc.2005.09.004. PMID: 16520270.
.
[22] Petrou A, Constantinidou A, Kontos M, Papalampros A, Moris D,
Bakoyiannis C, Neofytou K, Kourounis G, Felekouras E. Comprehensive
Surgical Treatment as the Mainstay of Management in Retroperitoneal
Sarcomas: Retrospective Study from Two Non-sarcoma Specialist Centers.
Anticancer Res. 2017 Apr;37(4):2025-2031. doi:
10.21873/anticanres.11547. PMID: 28373477.
[23] Raut CP, Pisters PW. Retroperitoneal sarcomas:
Combined-modality treatment approaches. J Surg Oncol. 2006 Jul
1;94(1):81-7. doi: 10.1002/jso.20543. PMID: 16788949.
[24] van Doorn RC, Gallee MP, Hart AA, Gortzak E, Rutgers EJ, van
Coevorden F, Keus RB, Zoetmulder FA. Resectable retroperitoneal soft
tissue sarcomas. The effect of extent of resection and postoperative
radiation therapy on local tumor control. Cancer. 1994 Feb
1;73(3):637-42. doi:
10.1002/1097-0142(19940201)73:3<637::aid-cncr2820730322>3.0.co;2-y.
PMID: 8299085.
Figure legand:
Figure 1. Axial T1-weighted fat-suppressed (A), T2-weighted (B), and
gadolinium-enhanced T1-weighted fat-suppressed (C) MR images show a
large relatively well-defined, homogeneous, non–fat-containing solid
intra-abdominal mass that is isointense to skeletal muscle on
T1-weighted images (arrows on A), heterogeneously T2 hyperintense
(arrows on B), and heterogeneously enhanced (arrows on C). Uterus=U on
A-C.
Figure 2. Axial gadolinium-enhanced T1-weighted fat-suppressed (A, B)
manifest normal uterus (arrow on A, B)and normal ovaries(arrow head on
A,B).
Figure3.Coronal and axial gadolinium-enhanced T1-weighted fat-suppressed
(A-C) MR images show right side hydroureteronephrosis(arrow on A and B)
and right external iliac vein(arrow on C).